NasdaqGS:ALNYBiotechs
Alnylam Pharmaceuticals (ALNY) Valuation Check After NASDAQ-100 Entry and $250m Manufacturing Expansion
Alnylam Pharmaceuticals (ALNY) just earned a spot in the NASDAQ 100, a move that can channel more passive money into the stock and highlights how far the RNAi pioneer has come with investors.
See our latest analysis for Alnylam Pharmaceuticals.
The NASDAQ 100 inclusion caps a strong run, with the share price up sharply year to date and a five year total shareholder return above 200 percent, as investors reward recent R and D progress and the 250 million dollar manufacturing expansion.
If...